Randomized phase iii study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (jcog0106)

Japanese Journal of Clinical Oncology

Volumn 43, Issue 10, 2013, Pages 972-980

  Shirao, Kuniaki ^a   Boku, Narikazu ^b   Yamada, Yasuhide ^c   Yamaguchi, Kensei ^d   Doi, Toshihiko ^e   Goto, Masahiro ^f   Nasu, Junichiro ^g   Denda, Tadamichi ^h   Hamamoto, Yasuo ⁱ   Takashima, Atsuo ^j   Fukuda, Haruhiko ^j   Ohtsu, Atsushi ^e  

^a OITA UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h CHIBA CANCER CENTER   (Japan)

ⁱ TOCHIGI CANCER CENTER   (Japan)

^j NATIONAL CANCER CENTER   (Japan)

more..

Author keywords

Chemotherapy; Gastric cancer; Peritoneal metastasis; Phase III study

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASCITES; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG INTOXICATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPONATREMIA; INTESTINE STENOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PERITONEUM TUMOR; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

CHEMOTHERAPY; GASTRIC CANCER; PERITONEAL METASTASIS; PHASE III STUDY;

ADULT; AGED; ANOREXIA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUTROPENIA; ODDS RATIO; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84885149501     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt114     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
3. Kang Y-K, Kang W-K, Shin D-B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-73.
4. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
5. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-53.
6. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450-7.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006;24:4991-7.
8. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-42.
9. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-9.
10. KoizumiW, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
11. Sakamoto T, Yasui H, Boku N, et al. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis. Int J Clin Oncol 2010;15:287-93.
12. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
13. Dupont JB, Lee JR, Burton GR, Cohn I. Adenocarcinoma of the stomach: review of 1497 cases. Cancer 1978;41:941-7.
14. Hiratsuka M, Iwanaga T, Furukawa H, et al. Important prognostic factors in surgically treated gastric cancer patients. Gan To Kagaku Ryoho 1995;22:703-8.
15. Fujimura T, Ishii K, Oyama K, et al. A new scoring system for peritoneal metastasis in gastric cancer. Gastric Cancer 2003;6:146-52.
16. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403.
17. Kim JG, Ryoo B-Y, Park YH, et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008;61:301-7.
18. Koo DH, Ryoo B-Y, Kim HJ, et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol 2011;68:913-21.
19. Yamao T, Shimada Y, Shirao K, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria. Jpn J Clin Oncol 2004;34:316-22.
20. Tamura S, Miki H, Okada K, et al. Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer. Gastric Cancer 2010;13:101-8.
21. Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010;21:67-70.
22. Ishizone S, Maruta F, Saito H, et al. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy 2006;52:301-7.
23. Hamaguchi T, Shirao K, Yamamichi N, et al. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial. Jpn J Clin Oncol 2008;38:432-7.
24. Konishi T, Hiraishi M, Mafune K, et al. Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 1994;14:1277-9.
25. Dickinson R, Presgrave P, Levi J, Milliken S, Woods R. Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. Cancer Chemother Pharmacol 1989;24:67-8.
26. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 1979;205:1135-7.
27. Fernandes DJ, Bertino JR. 5-Fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci USA 1980; 77:5663-7.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
29. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
30. DD LK. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
31. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994;12:960-9.
32. Lee J, Lim T, Uhm JE, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007;18:886-91.
33. Pérez JE, Lacava JA, Dominguez ME, et al. Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. Am J Clin Oncol 1998;21:452-7.
34. Takiuchi H, Fukuda H, Boku N, et al. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). Annual meeting of ASCO. J Clin Oncol 2010;28 (Suppl 4052).
35. Iwasa S, Nakajima TE, Nakamura K, et al. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. Gastric Cancer 2012;15:21-6.